

Talent Pool



EXECUTIVE APPOINTMENTS
AND PROMOTIONS IN THE
HEALTHCARE INDUSTRY

By Carolyn Gretton

► PHARMACEUTICAL POOL

Percival **BARRETTO-KO**

ASTELLAS REALIGNS EXECUTIVE TEAM



Astellas US, the U.S. affiliate of Tokyo-based Astellas Pharma, has named Percival Barretto-Ko senior VP, corporate strategy and government affairs. Mr. Barretto-Ko was previously executive director, corporate strategy and communications at Astellas Pharma Europe. He earned an MBA from Yale School of Management and an M.S. from MIT Sloan School of Management, where he recently served as a Sloan Fellow for Innovation and Global Leadership.

Greg **DEENER**

Taryn **JOSWICK**

Dr. Peter **LICHTLEN**

SUCAMPO MAKES LEADERSHIP SHIFTS



International pharma company Sucampo Pharmaceuticals has made a number of changes in its marketing and R&D leadership.



Greg Deener has joined Sucampo Pharma Americas (SPA) as VP of marketing, strategy and implementation. Mr. Deener is responsible for key marketing functions related to Sucampo's approved drugs in addition to playing a key role in developing global marketing strategies for Sucampo's pipeline compounds. He was most recently VP, marketing and sales for GTx.



On the R&D side, Gayle Dolecek, Sucampo's former senior VP, research and development, has stepped into a part-time role as executive advisor, R&D. Dr. Dolecek's responsibilities are being shared by Taryn Joswick, VP, clinical development of SPA, and Peter Lichtlen, M.D., Ph.D., senior medical officer and VP of European operations for Sucampo AG (SAG).

Ms. Joswick has been with Sucampo since 2001 and was promoted to her current position in August. Dr. Lichtlen joined SAG in July from Switzerland-based ESBATech. He received an M.D. and a Ph.D. in molecular biology from the University Of Zurich.

Dr. Rainer **METTERNICH**

ROCHE STRENGTHENS RESEARCH LEADERSHIP

Roche has appointed Rainer Metternich, Ph.D., head of small molecules research (SMR), a key part



of the global healthcare company's pharma research and early development (pRED) organization.

Dr. Metternich is responsible for overseeing the development of SMR's

mid- and long-term vision and strategy and guiding the group as it applies novel technologies to develop world-class compounds.

Dr. Metternich most recently served as chief scientific officer and chief business officer for Berlin-based Caprotec. Dr. Metternich received a Ph.D. in organic chemistry from Philipps University in Marburg, Germany.

► BIOTECHNOLOGY POOL

Adrian **ADAMS**

Andrew **KOVEN**

NEUROLOGIX ANNOUNCES LEADERSHIP TRANSITION



Neurologix, a biotechnology company engaged in the development of innovative gene therapies for disorders of the brain and central nervous system, has appointed Adrian Adams chairman and CEO. Mr. Adams is working toward strengthening the company's research and development, operations, and commercial infrastructures in support of Neurologix's lead compound, NLX-P101, which has demonstrated positive results to date in the treatment of Parkinson's disease.



Mr. Adams most recently was president and CEO of Inspire Pharmaceuticals.

In other moves, Andrew Koven has joined the Neurologix executive team as president and chief administrative officer, responsible for legal, intellectual property, corporate development and licensing, human resources, and general daily operations. Mr. Koven was previously executive VP and chief administrative and legal officer at Inspire Pharmaceuticals.

Dr. Andrew **CUBITT**

Dr. Jeffrey **GREVE**

ATYR PHARMA ADDS VPS



Protein therapeutics company aTyr Pharma has announced the addition of two VPs to its leadership team to support aTyr in the development of new breakthrough medicines based on physiocrine biology.

Andrew Cubitt, Ph.D., has been named VP, intellectual property. Dr. Cubitt previously served as executive director of corporate development for



Anaptys Biosciences, a company he co-founded in 2005. He received a Ph.D. in biochemistry from the University of Sheffield in the United Kingdom.

Jeffrey Greve, Ph.D., has joined aTyr as VP, research. Dr. Greve was most recently executive director, stem cell sciences at Exelixis. He received a Ph.D. in molecular biology at the Washington University School of Medicine in St. Louis.

► BIOPHARMACEUTICAL POOL

Dr. Joanne **DONOVAN**

FORMER GENZYME VP JOINS CATABASIS AS MEDICAL CHIEF



Catabasis Pharmaceuticals, a biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids for the treatment of inflammatory and metabolic diseases, has named Joanne Donovan, M.D., Ph.D., chief medical officer. Dr. Donovan is overseeing Catabasis' clinical development and regulatory strategy as the company prepares to begin human clinical trials of its lead program in type 2 diabetes.

Dr. Donovan joins Catabasis from Genzyme, where she was VP of clinical research. She holds a Ph.D. in medical engineering and medical physics from the Massachusetts Institute of Technology and an M.D. from Harvard Medical School.

Dr. Takashi Kei **KISHIMOTO**

NEW SCIENTIFIC CHIEF AT SELECTA BIOSCIENCES



Selecta Biosciences, a biopharmaceutical company developing novel targeted vaccines and immunotherapies, has appointed Takashi Kei Kishimoto, Ph.D., chief scientific officer.

Dr. Kishimoto brings to Selecta more than 20 years of experience as a pharmaceutical and biotechnology scientist and leader, most recently as VP of research at Momenta Pharmaceuticals. He received a Ph.D. in immunology from Harvard University.

Dr. Nancy **STAGLIANO**

IPIERIAN APPOINTS CHIEF EXECUTIVE

iPierian has named Nancy Stagliano, Ph.D., CEO, succeeding the company's interim CEO, Peter Van Vlasselaer, Ph.D., who has assumed the role of executive chairman. Dr. Stagliano was previously CEO and co-founder of CytomX Therapeutics. She re-



ceived an M.S. in biomedical engineering from Drexel University and a Ph.D. in neuroscience from the University of Miami.

iPierian is a biopharmaceutical company focused on harnessing the power of induced pluripotent stem cells to advance the understanding of human diseases and accelerate the discovery of more effective therapeutics for patients.

Dr. Karsten WITT

ARRAY BIOPHARMA NAMES CLINICAL VP



Array BioPharma has appointed Karsten Witt, M.D., VP of clinical sciences, leading clinical science and drug safety activities for Array's pipeline of targeted small-molecule drugs to treat cancer and inflammatory diseases.

Dr. Witt previously served as senior VP, pharmaceutical operations for OSI Pharmaceuticals. He received a medical degree from the University of Copenhagen.

► SPECIALTY POOL

Dominick DIPALO

TRIS PHARMA APPOINTS QUALITY VP



Tris Pharma, a specialty pharmaceutical company developing products based on its drug delivery technologies, has named Dominick DiPaolo VP of quality.

Mr. DiPaolo previously led quality operations at G&W Laboratories.

Dr. Erin DUFFY

Jarrold LONGCOR

RIB-X PROMOTES TWO EXECUTIVES



Rib-X Pharmaceuticals, a development-stage company with a pipeline of broad-spectrum antibiotics, has promoted Erin Duffy, Ph.D., to chief scientific officer. Dr. Duffy joined Rib-X early in 2002 and most recently served as VP of discovery research. She received a Ph.D. in physical-organic chemistry from Yale University.

In other moves, Jarrold Longcor has been promoted to VP, corporate development from senior director, business development.

Mr. Longcor received an MBA from St. Joseph's University's Erivan K. Haub School of Business and a master's of medicine from Boston University School of Medicine.

Martin DUVALL

ARIAD TAPS FORMER MERCK VP TO HEAD COMMERCIAL OPERATIONS



Ariad Pharmaceuticals has appointed Martin Duvall senior VP, commercial operations, responsible for leading the global commercialization of the company's oncology drug candidates. Mr.

Duvall joins Ariad from Merck, where he served as senior VP and general manager of the global oncology franchise. He earned a master's in chemistry from Johns Hopkins University and an MBA from the University of Kansas.

Dr. Dennis KIM

ENDOCRINOLOGIST JOINS ZAFGEN AS MEDICAL CHIEF



Zafgen, a pharmaceutical company pioneering novel obesity therapeutics, has named Dennis Kim, M.D., chief medical officer. Dr. Kim has primary responsibility for Zafgen's clinical devel-

opment activities, including clinical and regulatory strategy, trial design, and oversight of the company's virtual clinical team.

A board-certified endocrinologist, Dr. Kim joins Zafgen from Orexigen Therapeutics, where he held multiple senior-level clinical and corporate affairs positions, including senior VP, head of obesity/metabolic diseases; and senior VP, corporate development. He received an M.D. from the University of Health Sciences/The Chicago Medical School, and an MBA from the Rady School of Management at University of California, San Diego.

Kenneth MCBEAN

CORNERSTONE THERAPEUTICS NAMES PRESIDENT



Cornerstone Therapeutics, a specialty pharmaceutical company focused on developing, acquiring, and commercializing products for the respiratory,

hospital, and related specialty markets, has appointed Kenneth McBean president. Mr. McBean joins Cornerstone from Covidien, where he was VP and general manager of specialty pharmaceuticals.

► ASSOCIATION POOL

Dr. Glen STREAM

AAFP ANNOUNCES PRESIDENT

Glen Stream, M.D., a family physician in Spokane,



Wash., has assumed the role of president of the American Academy of Family Physicians.

Dr. Stream previously served three years as a director on the AAFP Board and one year as president-elect. The AAFP represents 100,300 physicians and medical students nationwide.

Dr. Stream earned a medical degree from the University of Washington School of Medicine and a master of biomedical informatics degree from Oregon Health and Science University.

► AGENCY POOL

Elaine ANDRECOVICH

Arielle BERNSTEIN

MAKOVSKY + COMPANY STRENGTHENS HEALTH PRACTICE



Independent public relations agency Makovsky + Company has added two team members with extensive oncology sector experience to its health practice.



Makovsky has named Elaine Andreovich account supervisor.

Ms. Andreovich brings five years' experience in healthcare PR and communications strategy, including media and advocacy relations for oncology clients and disease awareness, regulatory issues management, and crisis communications for pharmaceutical clients.

Arielle Bernstein rejoins Makovsky's health practice team as VP. Ms. Bernstein maintains a post as research manager for the University of Chicago's biological sciences division, department of pediatric hematology/oncology.

She holds a master's degree in public policy from the University of Chicago.

Bronwen KAYE

FORMER PFIZER DIRECTOR JOINS APCO WORLDWIDE



Bronwen Kaye, former senior director of government relations for Pfizer, has joined global communication consultancy APCO Worldwide's healthcare practice as a senior advisor.

Ms. Kaye has more than 25 years of executive-level experience in government relations for the healthcare sector, having led numerous legislative advancements in immunization, biotechnology, medical research, and other areas of medicine.

Talent Pool

Leo KOSIR
Mike WILLIAMS
**ABELSONTAYLOR STRENGTHENS
ART TEAM**


Independent healthcare advertising agency AbelsonTaylor has added two senior art directors to its creative team.



Leo Kosir is an award-winning graphic designer with more than 17 years of design and marketing experience, most recently as creative director with ARS Advertising.

At AbelsonTaylor, Mr. Kosir is responsible for products in the areas of gastroenterology and hepatitis.

Mike Williams joins AbelsonTaylor after a freelance stint for the agency.

As a senior art director, Mr. Williams continues his work on a baby formula account, directing teams that will be developing both interactive and print initiatives.

Betsy KRAMER
TOPIN BOLSTERS ACCOUNTS TEAM


Betsy Kramer has joined healthcare agency Topin & Associates as an account director. Ms. Kramer is overseeing the day-to-day management for several accounts, including Myriad Genetics, Mission Pharmacal, and Quest Diagnostics. She is also involved in brand strategy development.

Ms. Kramer most recently worked for Corbett Accel Healthcare Group (CAHG), where she led the global Bristol-Myers Squibb account and CAHG's clinical trial recruitment practice.

Jack LIPTON
**INTOUCH SOLUTIONS OPENS
NEW YORK OFFICE**


Intouch Solutions, a marketing agency servicing the pharmaceutical industry, has hired Jack Lipton as senior VP, client services based in its recently opened New York office. Mr. Lipton brings to Intouch extensive pharma marketing experience through agencies such as G2 and MRM.

The new location expands the agency's presence to the East Coast to service existing clients as well as lays the groundwork for expanded services, products, and talent. In addition to New York, Intouch has offices in Overland Park, Kan., and Chicago.

Patrick PURCELL
SCS HEALTHCARE SELECTS SALES VP


SCS Healthcare Marketing, a division of HealthSTAR Communications, has appointed Patrick Purcell VP of sales to lead the healthcare communications company's business development group. Mr. Purcell was previously VP of sales and marketing for PharmaTouch.

Dr. Laurie SMALDONE
PHARMAPPROVE TAPS FORMER BRISTOL-MYERS SQUIBB VP AS PRESIDENT


Laurie Smaldone, M.D., has joined strategic regulatory communications firm PharmApprove as president. Dr. Smaldone is leading PharmApprove's team of regulatory communications and product development specialists in expanding the company's services and its geographic reach.

Dr. Smaldone's experience includes a stint as senior VP of global regulatory science at Bristol-Myers Squibb. She was most recently CEO of an unnamed clinical-phase biotechnology company. Dr. Smaldone received an M.D. from Yale University.

► CONSULTING POOL
Ron JOHNSON
**FORMER FDA DIRECTOR NAMED
BECKER CONSULTING PRESIDENT**


Becker & Associates Consulting (Becker Consulting) has named as president Ron Johnson, former director of the Office of Compliance within the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA). Mr. Johnson has a 30-year career at the FDA, combined with 14 years of proven skill managing complex consulting endeavors in FDA-regulated industries.

Dr. Jean-Olivier MARTY
INSTAR EXPANDS INTO EUROPE, ASIA


Instar, a provider of fast and cost-effective market research services to the pharma industry, has appointed Jean-Olivier Marty, Pharm.D., director of European business development in conjunction with the launch of its Instar OnDemand online quantitative research service in Europe and Asia.

Dr. Marty joins Instar from Synovate Healthcare, where he most recently served as a research director heading up the specialized autoimmune team within the company's global therapy monitors team. He holds a Pharm.D. from Université Paris XI and an MBA from ESSEC Business School in France.

Samrat SHENBAGA
**ZS ASSOCIATES ESTABLISHES
SAN DIEGO OFFICE**


Global consulting firm ZS Associates has named Principal Samrat Shenbaga to lead its newly established San Diego office, the company's third in California. ZS Associates offers a broad range of consulting services to companies in healthcare, technology, financial services, transportation, and other industries.

Mr. Shenbaga has been with ZS Associates since 1998 and has worked closely with clients in southern California since 2007, guiding complex sales and marketing transformations. He earned an MBA from the Stern School of Business at New York University.

► CRO POOL
Dr. Oren COHEN
**QUINTILES TAPS MEDICAL CHIEF AS
PHASE I CLINICAL HEAD**


Quintiles has appointed Oren Cohen, M.D., senior VP and global head of its Phase I clinical research division, which includes facilities in Overland Park, Kan., London, and Hyderabad, India. Dr. Cohen is leveraging Quintiles' breadth of clinical trial services and expertise in biomarker development to provide sponsors with an integrated early clinical development platform that reduces overall study costs, simplifies trial management, and accelerates development, while ensuring quality and patient safety.

Dr. Cohen was previously Quintiles' chief medical and scientific officer. He received an M.D. from Duke University School of Medicine.

Dr. Jasmine (Jisong) CUI
Raymond HILL
PPD APPOINTS NEW LEADERSHIP

PPD has appointed Jasmine (Jisong) Cui, Ph.D., chief scientific officer of BioDuro, providing scientific leadership to the subsidiary's integrated drug discovery services across a range of disease areas and expanding its use of novel technologies for



small and large molecules and in stem cells and imaging.

Dr. Cui previously served as VP and head of drug discovery and translation for an unnamed biotech company. She received a Ph.D. in biology from Purdue University.



In other moves, Raymond Hill has been appointed CEO of PPD. Mr. Hill joins PPD after eight years at IMS Health, where he most recently served as president of IMS Consulting Group. He holds a master's degree from Duke University.

► MEDIA POOL

Paul SLAVIN

FORMER ABC NEWS EXECUTIVE JOINS EVERYDAY HEALTH



Everyday Health, a digital publisher of health information, has named Paul Slavin senior VP and general manager, global news of Everyday Health Studios, reflecting the company's expanding operations in video and health newsgathering and reporting. Mr. Slavin joins Everyday Health after more than three decades with ABC News, where he was most recently senior VP, new media.

Mr. Slavin's responsibilities include developing future opportunities for the company's professional business unit, MedpageToday, and for leading a new video unit, Everyday Health Studios, which encompasses video operations across the Everyday Health portfolio and the recently launched Everyday Health television series.

► SERVICE POOL

Dr. Emma BANKS

DATATRIAL PROMOTES CHIEF EXECUTIVE



company.

Boutique clinical data management firm Datatrial has promoted Chief Operations Officer Emma Banks to CEO. Dr. Banks succeeds Adam Black, who remains a nonexecutive director of the

Jack BUSH Henry PROLOG

WOLTERS KLUWER PHARMA SOLUTIONS STRENGTHENS ANALYTICS LEADERSHIP

Wolters Kluwer Pharma Solutions, a provider of sci-



entific information and analytics to pharmaceutical and healthcare professionals, has announced the addition of two VPs.



Jack Bush has been appointed VP, marketing for the healthcare analytics business. Mr. Bush has 25 years of experience in senior management roles at a number of pharma companies. He

holds an M.A./MBA from Indianapolis University.

Henry Prolog has joined Wolters Kluwer Pharma Solutions as VP, data strategy, acquisitions and services. Mr. Prolog's responsibilities include managing the supply of data and information sets from PBMs, wholesalers, retail pharmacies, and hospitals and setting data strategy for the company's healthcare analytics business.

Mr. Prolog has more than 25 years of sales, data contracts, and marketing experience in the healthcare, technology, and information industries. He was most recently with US Oncology. Mr. Prolog received an MBA from the University of Munich.

Dr. Suzanne DALE Sara DIAZ

ACM GLOBAL STRENGTHENS MEDICAL EXPERTISE



Clinical research services provider ACM Global Central Lab has appointed Suzanne Dale, Ph.D., director of microbiology, with responsibility for both microbiology and molecular diagnostics. Before joining ACM, Dr. Dale was assistant professor at McMaster University in Hamilton, Ontario, and held a clinical scientist position within the Hamilton Regional Laboratory Medicine Program. She received a Ph.D. in microbiology and immunology from the University of Western Ontario.

Sara Diaz has been named manager of hematology. Ms. Diaz has more than two decades of experience in laboratory science, most recently as core laboratory operations manager for Abington Memorial Hospital.

She holds a master's degree in information systems from Pace University.

Jackie KWAN

MEDEFIELD EXPANDS ASIA TEAM



Hong Kong. Ms. Kwan is responsible for advising

and servicing clients looking to field physician fieldwork studies across Asia.

She brings to Medefield experience in both on-line and offline fieldwork, both on the supplier and agency sides.

Michael SPEDDING

P\S\L GROUP NAMES DOMAIN CEO



The P\S\L Group has appointed Michael Spedding domain CEO, encompassing all of the group's market research businesses in Europe and the Americas.

Mr. Spedding is responsible for leading key initiatives such as broadening product portfolios and expanding geographical presence, as well as growing the management teams and talent of the group's individual businesses.

He was previously CEO, geographies at Synovate Healthcare.

► TECHNOLOGY POOL

Linda DEAL

ERT SELECTS HEAD OF HEALTH OUTCOMES RESEARCH



ERT, a global provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations, has appointed Linda Deal to lead its health

outcomes research initiatives.

Ms. Deal was most recently immunology patient reported outcomes (PRO) lead at Janssen Pharmaceuticals.

Dr. John HARRISON

CRF HEALTH BOLSTERS CNS-RELATED CONSULTING EXPERTISE



CRF Health, a global provider of ePRO solutions to the life-sciences industry, has appointed John Harrison, Ph.D., scientific consultant.

Dr. Harrison is charged with providing advice on both patient and clinician reported outcomes in central nervous system (CNS) related clinical studies.

Dr. Harrison has more than 15 years of extensive experience in selection and integration of cognitive testing into drug development programs, most recently as principal scientist for CogState.

He received a Ph.D. in neuroscience from the University of London.

Talent Pool

► **MORE PHARMACEUTICAL POOL****Dr. Mahmoud GHAZZI****DAIICHI SANKYO PHARMA DEVELOPMENT NAMES VP**

Mahmoud Ghazzi, M.D., Ph.D., has joined Daiichi Sankyo Pharma Development (DSPD) as executive VP of drug development for the Americas region. DSPD is responsible for the regional delivery of Daiichi Sankyo's global clinical trials throughout North, South, and Central America.

Dr. Ghazzi is working with Daiichi Sankyo's global development regional heads in Asia, Japan, and Europe. He also serves as the co-chair for the Daiichi Sankyo Global Clinical Committee.

Dr. Ghazzi holds a master's in public health and a Ph.D. in biomedical engineering from the University of Michigan.

Dr. Eddie LI**NOVO NORDISK APPOINTS REGULATORY VP**

Eddie Li, Ph.D., has joined global healthcare company Novo Nordisk as VP, regulatory affairs. Dr. Li leads Novo Nordisk's U.S. regulatory team and maintains relationships with key individuals and agencies outside of Novo Nordisk.

Dr. Li was most recently with Sanofi, where he served as global head of regulatory affairs for one of the company's largest therapy areas. He received a Ph.D. in toxicology from the University of Arkansas for Medical Sciences.

► **MORE BIOTECHNOLOGY POOL****Robert LOLLINI****MYREXIS FINANCIAL CHIEF PROMOTED TO CEO**

Myrexis, a biotechnology company focused on the development of small molecule compounds for oncology and autoimmune disease treatment, has named Robert Lollini CEO.

Mr. Lollini joined Myrexis in 2009 as chief financial officer and treasurer and has been serving as Myrexis' interim president and CEO.

He received an MBA in finance/economics from the University of Detroit.

► **MORE BIOPHARMACEUTICAL POOL****Dr. Abbie CELNIKER****Chen SCHOR****ELEVEN BIOTHERAPEUTICS APPOINTS LEADERSHIP**

Eleven Biotherapeutics, a biopharmaceutical company focused on engineering and developing innovative protein-based therapeutics, has named Abbie Celniker, Ph.D., CEO. Dr. Celniker was previously president and CEO for Taligen Therapeutics, which was acquired by Alexion in January 2011.

Eleven Biotherapeutics has also announced the addition of biotechnology executive Chen Schor as chief business officer. Mr. Schor was most recently VP, business development, global branded products at Teva Pharmaceuticals.

Dr. George KEMBLE**3-V BIOSCIENCES APPOINTS SCIENTIFIC CHIEF**

3-V Biosciences has named George Kemble, Ph.D., chief scientific officer. Dr. Kemble joins 3-V from MedImmune, where he most recently served as senior VP of R&D and head of research. He received a Ph.D. from Stanford University.

3-V is a privately held biopharmaceutical company dedicated to discovering, developing, and ultimately commercializing novel antiviral therapeutics that target host cell factors required for viral infection, thereby avoiding many of the shortcomings of traditional pathogen-directed approaches.

► **MORE SPECIALTY POOL****Dr. Kelly HUANG****NEW PRESIDENT FOR ENDO'S HEALTHTRONICS SUBSIDIARY**

Endo Pharmaceuticals has named Kelly Huang, Ph.D., president of its HealthTronics subsidiary, which provides urological products and services. Dr. Huang was previously VP of research & development at Neutrogena. Endo is a specialty healthcare solutions company operating in three key business segments: branded pharmaceuticals, generics and devices, and services. He received both a master's degree and a Ph.D. in chemical engineering from Stanford University.

Dr. Theron (Ted) ODLAUG**PLANET BIOPHARMACEUTICALS NAMES CEO**

Planet Biopharmaceuticals, a privately held specialty pharmaceutical company providing products for allergy and asthma sufferers, has appointed Theron (Ted) Odlaug, Ph.D., executive chairman and CEO. Dr. Odlaug was most recently president and CEO of CyDex Pharmaceuticals, which was sold to Ligand Pharmaceuticals earlier this year. He has a master's degree from the University of Missouri-Kansas City and a Ph.D. in public health from the University of Minnesota.

► **MORE DIAGNOSTICS POOL****Jeff HAYES****COMBIMATRIX SELECTS ONCOLOGY SALES DIRECTOR**

CombiMatrix, a molecular diagnostics company performing DNA-based testing services for cancer and developmental disorders, has appointed Jeff Hayes director of sales for the oncology market. Mr. Hayes has more than two decades of experience in the cancer diagnostics industries.

► **MORE SERVICE POOL****Gregory ELLIS****IMPACTRX APPOINTS CHIEF EXECUTIVE**

ImpactRx, a provider of validated, consultative analytical models that demonstrate the impact of promotion on physician prescribing behavior, has named Gregory Ellis president and CEO. Mr. Ellis joins ImpactRx from Rosetta, where he was senior partner. He received an MS in industrial administration from Carnegie Mellon University.

Dr. Paul JENKINS**CATALENT APPOINTS DEVELOPMENT VP**

Catalent Pharma Solutions, a provider of drug and biologic development, technology, and supply services, has named Paul Jenkins, Ph.D., global VP, business development, Zydis technology. Before joining Catalent, Dr. Jenkins was CEO of Adjuvantix. He holds a Ph.D. in immunology from the University of Plymouth, United Kingdom. **PV**

New Paradigms to Fund & Move Drug Development

The Interface between Finance & Clinical Development to Secure Investment

January 11 - 12, 2012

Marines' Memorial Club & Hotel, San Francisco, CA

Conveniently Co-Located by the JP Morgan Healthcare Event

HIGHLIGHTS

Conference Leadership



Sandra S. Garrett, PhD
Executive Chair
Global Research
Services, LLC



Peter G. Milner, MD, FACC
Co-founder
CV Therapeutics,
ARYx, and Optivia
Biotechnology



Karen Bernstein, PhD
Chairman and
Editor-in-Chief
BioCentury



David Flores
Chief Executive
Officer
BioCentury

Anticipated Market Disruptions Feature



George Bickerstaff
Managing Director
MM Dillion & Co



David Pyott, CBE
Chairman of the
Board and Chief
Executive Officer
Allergan



Greg Simon
Senior Vice
President, Patient
Engagement
Pfizer



John Orloff, MD
SVP, Global
Development &
CMO,
Novartis

Regulatory Success Keynote

Future of Clinical Trials Feature

Chief Medical Officer Insights

A joint program for Biotech CEOs, Investors, Pharmaceutical Business Development & R&D Leaders

January 11th

- ✓ New Paradigms to secure investment through alternative sources of funding and non-traditional partnering strategies

January 12th

- ✓ New Paradigms to secure investment through innovative approaches to drug development and approval for the successful commercialization of new therapies

Onsite networking partnering services available

**15% off
for PharmaVoice
readers with
Code PVNP**

Executive Sponsors



Co-Sponsors

Supporting Partners



Media Partner



Organized by



TO REGISTER OR FOR MORE INFORMATION, VISIT WWW.THECONFERENCEFORUM.ORG OR CALL 646-350-2580